ACTRN12613000925741已完成3 期
A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal formulation containing Testofen, on symptoms of Andropause and serum testosterone levels in otherwise healthy males aged between 45-75 years.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 45 Years 至 75 Years（—）
- 性别
- Male
入选标准
- •Heterosexual male aged between 45-75
- •Otherwise healthy
- •Written informed consent from the subject
排除标准
- •Subjects will be excluded for any one of the following reasons:
- •Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion
- •Known hypersensitivity to herbal drugs/nutritional supplement/ foods
- •Any physical disability that may limit sexual function or erectile dysfunction
- •Received any treatment/therapy I(including testosterone) for any sexual disorder during last 6 months
- •Receiving/ prescribed coumandin (Warfarin), heparin, daltaparin, enoxaparin or other anticoagulation therapy
- •Receiving/ prescribed levodopa (Sinemet) for Parkinson’s Disease or calcipotriene (Dovonex) for Psoriasis
- •Diagnosed with hypertension and receiving/ prescribed antihypertensive medications
- •Diagnosed severe renal and/or hepatic insufficiency
- •Diagnosed genital anatomical deformities, uncontrolled diabetes mellitus, and history of spinal cord injury, uncontrolled psychiatric disorder, and/or abnormal secondary sexual characteristics
- •Diagnosed prostatic cancer or benign hypertrophy; if suspected by the investigator, refer for medical assessment
- •Acute genitourinary disorder
- •History of genital surgery
- •Current or history of chronic alcohol and/or drug abuse
- •Suspected or diagnosed chickpea allergy
- •Participation in any other clinical trial during last 30 days
- •Simultaneous participation in another clinical trial
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltransferase activity and motor response in parkinson´s disease patients treated with levodopa/dopa-decarboxylaseinhibitorParkinson’s DiseaseMedDRA version: 17.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 100000004852EUCTR2009-012897-12-ROBIAL-Portela & Ca, SA32
已完成
3 期
A double-blind, randomised, placebo-controlled study to evaluate the effect of orally-dosed LipiSperse curcumin and/or palmitoylethanolamide (PEA) on exercise recovery in healthy males.Exercise recoveryAlternative and Complementary Medicine - Herbal remediesACTRN12618000285257RDC Global Pty Ltd42
已完成
不适用
A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal formulation containing Testofen, on sexual function, performance, and serum testosterone levels in healthy males.Sexual performanceSexual functionAlternative and Complementary Medicine - Herbal remediesMetabolic and Endocrine - Other metabolic disordersACTRN12611000830998AZPA International60
进行中（未招募）
1 期
Clinical trial to assess the effect of SNF472 on progression of build up of calcium in coronary blood vessels in patients with kidney disease.EUCTR2016-002834-59-ESaboratoris Sanifit450
进行中（未招募）
1 期
Clinical trial to assess the effect of SNF472 on progression of build up of calcium in coronary blood vessels in patients with kidney disease.Cardiovascular calcification in blood vessels in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).MedDRA version: 20.1 Level: LLT Classification code 10014646 Term: End stage renal disease (ESRD) System Organ Class: 100000004857MedDRA version: 20.0 Level: PT Classification code 10051753 Term: Vascular calcification System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: PT Classification code 10018875 Term: Haemodialysis System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002834-59-GBSanifit Therapeutics S.A.270